In prostate cancer, MSI2 can bind to the 3’-UTR region of androgen receptor (AR) mRNA, enhancing its mRNA stability and translation activity, and regulating the PI3K/AKT/mTOR pathway [40]. The gene discussed is MTOR; the disease is prostate carcinoma.